Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
about
Novel agents in the treatment of multiple myeloma: a review about the futureEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityNovel strategies to target the ubiquitin proteasome system in multiple myelomaSpotlight on ixazomib: potential in the treatment of multiple myelomaThe 26S proteasome is a multifaceted target for anti-cancer therapiesMagic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingThe non-canonical functions of the heme oxygenasesSmoldering multiple myeloma.Trial Watch: Proteasomal inhibitors for anticancer therapyPhase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibPharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyExposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Oral therapy for multiple myeloma: ixazomib arriving soon.New developments in the management of Waldenström macroglobulinemiaTM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibitionThe Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisPharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairmentBortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.Role of the ubiquitin proteasome system in hematologic malignancies.Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based PharmacokinetThe investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.Ixazomib for the treatment of multiple myeloma.
P2860
Q26745924-C553DA56-D8AA-4AA1-BF9C-C640AD764F57Q26771331-14941611-64DC-4C9A-AF90-88ACF9D706BFQ26773246-645EDEC6-93A2-45ED-BFAD-1848292659BBQ26774440-3D3B37B3-F3C5-410A-A398-26B605ED34C7Q26795764-E5104776-352E-497F-A1A1-F8AFDBE9D1C2Q28075816-DE96574D-B317-4FFB-89E7-61B0D32B3A93Q28077113-AB618B68-0847-4E47-914D-823AFBD4492BQ28082855-18323041-AEA7-4027-9490-4915795E9D50Q28082910-28F15A85-78FE-4CED-9AF6-78AC5FDD7C67Q33415759-52C2EAA6-5588-4198-9B5B-6EDB54E48383Q33418257-B02E3430-6550-4028-A67E-52AB456393BEQ33421241-EE2D422D-0E5A-4408-8407-C528BC505873Q33425190-6F4F1E00-4D82-45F4-8696-C89BB0A44AFCQ33425607-23F4F6D0-E0C8-48C9-AAE4-5D6BB6108DC6Q33431175-1806826F-A99D-4558-AC6C-708C978D0AD6Q33437790-5DC561A7-95F2-422C-8211-09B3D1CD512CQ33438839-0F71C7E8-F252-4210-A4B2-BAAD52CA9D33Q33441702-DB57D5E9-0134-4D57-8B70-9B0988C98A4CQ33627312-9FDF1B04-9069-403D-876F-4A881585B5EFQ34047916-CB871D14-30FC-4324-B0C4-6E2D75A7E612Q34553880-9D89B3EE-B945-4D25-B897-756C3678DABBQ35538460-8E81D4F1-5B72-45A9-AB7D-49B713B9FDC6Q35889653-3F1E0FB8-BA97-4307-87E1-A507BBDE8897Q35895152-B70EBF05-3AF4-4F9B-A5BD-74219328A008Q35969785-4C998805-2FAF-4A5B-B9CB-ECBD61637E1DQ36307049-BD46779B-84AF-4601-904A-F61859327755Q36750467-41E8F97B-5709-4BD6-B8E2-B6EC3DA15C08Q37058114-0592D0E8-35BE-48EA-9B2F-B33516A28074Q37077410-5DFDBA71-F71F-426D-BCF7-E66B39A3C3C7Q37348913-5A7B36A1-B1B9-479A-BE6A-0F4E22114C85Q37375516-344F9459-D9BF-469C-B034-12B99D391008Q37384878-2DAAA61D-F8BA-4CC4-9140-792D996759B7Q37644930-EF243EC7-AAC7-4583-93C7-4462E5322D2CQ37697141-9F6384A7-E3CC-48FC-8CD3-6DDC0403262BQ38289055-9EAB26E4-1F5E-4413-BAA2-7354EAA9336FQ38372360-B1E624FA-3832-472B-8378-7791458657CBQ38400460-D66C79C4-8977-4797-A465-0ECD071AFC32Q38462720-E7DA2A9E-FFFE-4630-8B89-D02F253B6358Q38503345-3DB99403-6F4F-433C-A5C8-D324F2AA4416Q38542172-E366EB31-DCD7-4A36-9913-15055C133FB8
P2860
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase 1 study of twice-weekly ...... tory multiple myeloma patients
@ast
Phase 1 study of twice-weekly ...... tory multiple myeloma patients
@en
type
label
Phase 1 study of twice-weekly ...... tory multiple myeloma patients
@ast
Phase 1 study of twice-weekly ...... tory multiple myeloma patients
@en
prefLabel
Phase 1 study of twice-weekly ...... tory multiple myeloma patients
@ast
Phase 1 study of twice-weekly ...... tory multiple myeloma patients
@en
P2093
P2860
P1433
P1476
Phase 1 study of twice-weekly ...... tory multiple myeloma patients
@en
P2093
Ai-Min Hui
Alessandra Di Bacco
Andrzej J Jakubowiak
Deborah Berg
Guohui Liu
Jacob P Laubach
Michael Wang
Moshe Talpaz
Neeraj Gupta
P2860
P304
P356
10.1182/BLOOD-2014-01-548826
P407
P577
2014-06-11T00:00:00Z